Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
75 participants
INTERVENTIONAL
2010-10-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The new RV autothreshold algorithm which will help the physician in his diagnosis avoiding potential lost of capture.
Then, the ICD devices have also the capability to be remotely interrogated through the remote monitoring system whose performances will be reported during the study.
Finally the study will report the electrical and handling performances of the new left ventricular lead.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Status Monitoring in Implantable Cardiac Defibrillator (ICD) Patients by Physiological Diagnosis (PhD) Function
NCT01170624
Clinical Evaluation Of The SonR Atrial Lead In Paradym RF Device
NCT01169272
Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device
NCT02167789
Master Study of the Acticor/Rivacor ICDs/CRT-Ds and the Plexa ProMRI S DX Lead
NCT03891329
Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device
NCT00957541
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Demonstrating the performances of the right ventricular autothreshold algorithm ;
* Reporting the adverse events documented in the study;
* Reporting electrical performances of Sorin Group PARADYM ICDs, in order to validate that the performances of those devices are in conformance with longevity and effectiveness objectives;
* Assessing the user satisfaction (patient and physician) of the remote monitoring solution and the overall availability of the system in terms of data.
* Reporting the Situs 2 MV left ventricular lead performances;
* Reporting the Situs 2 MV LV lead mechanical handling.
Thus, this study intends to show that PARADYM RF ICDs operate safely and appropriately in intended-use as part of an ICD system.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paradym RF ICD
Active implantable defibrillators range
VR 9250 / DR 9550 / CRT 9750
Active implantable defibrillators range
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VR 9250 / DR 9550 / CRT 9750
Active implantable defibrillators range
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In case of implantation of DR 9550: patient has been prescribed the implantation or replacement of a dual-chamber ICD system accordingly to the relevant currently-approved ACC/AHA/ESC2 guidelines or any relevant currently-approved local guidelines for the implantation or replacement of dual-chamber ICD;
* In case of implantation of CRT 9750: patient has been prescribed the implantation or replacement of a triple-chamber ICD system accordingly to the relevant currently-approved ACC/AHA/ESC3 guidelines or any relevant currently-approved local guidelines for the implantation or replacement of triple-chamber ICD;
Exclusion Criteria
* 2 VT/VF occurred during the acute phase of infarction (\< 3 weeks) or during an unstable ischemic phase;
* 3 VF was caused by electrocution;
* 4 Incessant VT/VF ;
* 5 Implanted pacemaker that is not going to be explanted or otherwise disabled;
* 6 Patient is unable to attend the scheduled follow-ups at the implanting centre;
* 7 Patient is already enrolled in another ongoing clinical study;
* 8 Patient is unable to understand the aim of the study and its procedure;
* 9 Patient refuses to cooperate;
* 10 Patient is unable or refuses to provide informed consent;
* 11 Patient is minor (less than 18-year old);
* 12 Patient is pregnant;
* 13 Patient has life expectancy of less than 1 year;
* 14 Patient is forfeiture of freedom or under guardianship.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LivaNova
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sack SS Stefan, Pr
Role: PRINCIPAL_INVESTIGATOR
Klinikum Schwabing München Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sack
München, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ITSY03 - PARADYM RF STUDY
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.